Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
25.08
-0.61 (-2.37%)
Nov 17, 2026, 3:00 PM CST
SHA:688319 Revenue
Chengdu Olymvax Biopharmaceuticals had revenue of 237.61M CNY in the quarter ending September 30, 2026, with 18.17% growth. This brings the company's total for the last twelve months to 796.18M, up 12.27% year-over-year. In the year 2025, Chengdu Olymvax Biopharmaceuticals had annual revenue of 704.16M with 19.58% growth. That makes Chengdu Olymvax Biopharmaceuticals the 21,402nd largest company in the world by revenue and 3,923rd in China.
Revenue (ttm)
796.18M
Revenue Growth
+12.27%
P/S Ratio
12.77
Revenue / Employee
1.83M
Employees
436
Market Cap
10.17B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 704.16M | 115.30M | 19.58% |
| Dec 31, 2024 | 588.86M | 92.74M | 18.69% |
| Dec 31, 2023 | 496.12M | -51.36M | -9.38% |
| Dec 31, 2022 | 547.48M | 60.33M | 12.38% |
| Dec 31, 2021 | 487.15M | 167.04M | 52.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.16B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Nanjing Vazyme Biotech | 1.56B |
| Shanghai Medicilon | 1.54B |
| BrightGene Bio-Medical Technology | 1.34B |
| Acrobiosystems | 1.03B |
| Shanghai OPM Biosciences | 822.13M |